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Obstructive sleep apnoea (OSA) carries an increased risk of ischaemic stroke, but the underlying mechanism is not clear. As right-
to-left shunting can occur through a patent foramen ovale (PFO) during periods of apnoea, we investigated nocturnal changes
in fibrinolytic activity and platelet function in subjects who had OSA with or without PFO and in controls. We determined
plasminogen activator inhibitor 1 (PAI-1) activity and antigen and platelet activation parameters. The severity of OSA was verified
by polygraphy and PFO was detected by ear oximetry. We found a higher PAI-1 activity and antigen and a lower ratio of 2,3-dinor-
PGF1α to 2,3-dinor-TXB2 in the subjects with OSA than in the controls. Linear regression analysis showed the apnoea-hypopnoea
index (β-coeﬃcient, 0.499; P = 0.032) and PFO (β-coeﬃcient, 0.594; P = 0.015) to be associated independently with PAI-1 activity
in the morning, while the increment in PAI-1 : Ag from evening to morning was significantly associated with the presence of PFO
(rs = 0.563, P = 0.002). Both OSA and PFO reduce fibrinolytic activity during nocturnal sleep. We hypothesize that subjects
having both OSA and PFO may develop a more severe prothrombotic state during sleep than those having either OSA or PFO
alone.
1. Introduction
Obstructive sleep apnoea (OSA) carries increased risks of
hypertension, ischaemic stroke, myocardial infarction, and
atrial fibrillation [1–6]. OSA occurs in up to 5% of the
adult population in western countries [1, 2], and aﬀected
subjects show increased platelet and reduced fibrinolytic
activity relative to controls [7]. OSA thus seems to be linked
to cardiovascular diseases via a hypercoagulable state. Other
factors may also contribute to this hypercoagulable state, but
their role is unclear. One possible factor is a patent foramen
ovale (PFO).
Many, although not all, studies have suggested an associ-
ation between PFO, which is present in about one-quarter
of adults, and ischaemic stroke [8–10]. The mechanism
of stroke in patients with PFO is still unclear. Paradoxical
embolism is considered the most likely mechanism, but it
has rarely been proved, and it has been suggested that a
hypercoagulable state may also be involved [10]. Transient
atrial arrhythmias do occur in the presence of PFO [11],
and, accordingly, OSA and PFO may act in concert to
precipitate thrombus formation in the left atrium involving
a hypercoagulable state together with atrial fibrillation.
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The present study was designed to show whether OSA
with PFO can produce a more severe hypercoagulable
state during nocturnal sleep than OSA or PFO alone. We
measured some key parameters of fibrinolysis and platelet
function before and after nocturnal sleep in subjects who
had OSA with or without PFO and in controls. These
parameters were plasminogen activator inhibitor 1 (PAI-
1) activity and antigen, shear-induced platelet aggregation
(SIPA) and urinary excretion of the major thromboxane
and prostacyclin metabolites. PAI-1, continuously produced
in platelets [12], is the main physiological plasminogen
activator-inhibitor with proatherogenic eﬀects [13], and it
has been reported to be induced by hypoxia [14]. SIPA
was chosen as a measure for platelet aggregation because it
may reflect more closely than other techniques the situation
encountered by platelets in stenosed arteries or arterioles
undergoing vasospasm [15]. The key metabolites of throm-
boxane (a potent vasoconstrictor and platelet aggregator)
and prostacyclin (a potent vasodilator and inhibitor of
platelet aggregation), 2,3-dinor-TXB2 and 2,3-dinor-PGF1α
were chosen because they reflect platelet and endothelial
functions in vivo.
2. Subjects and Methods
The protocol was approved by the Ethics Committee of the
Medical Faculty, University of Oulu. Informed consent was
obtained from all the subjects. Fifty-three subjects admitted
for overnight sleep recording because of suspected sleep
apnoea were recruited. Forty-eight subjects were initially
investigated at our in-patient department by in-laboratory
polysomnography and 5 had portable monitoring at home.
After sleep recording 24 of them were diagnosed to have
OSA. The rest (n = 29) did not have OSA and served as
controls for those with OSA. Information on the subject’s
use of medication, previous diseases, height, and weight
was obtained. Although all the subjects had been asked to
stop daily intake of anti-inflammatory drugs for two weeks
preceding blood sampling, 14 of them, 7 in the OSA group
and 7 in the control group, had taken nonsteroidal anti-
inflammatory drugs (NSAIDs). Subjects were considered to
be hypertensive if their blood pressure readings had exceeded
160/90mmHg (as proposed in the WHO/ISH statement)
[16] at least twice, or if they were taking antihypertensive
medication. Previous strokes, diabetes, and cardiac diseases
including atrial fibrillation were recorded. The subjects were
asked to avoid exercise for one day before admittance. Blood
samples were taken at 6 p.m., 10 p.m., 2 a.m., and 6 a.m., but
on a separate day apart from sleep recording (usually one day
after the day of sleep recording). Urine samples were gathered
for a period immediately before (from 10 a.m. to 6 p.m.) and
during sleep recording (from 10 p.m. to 6 a.m.). All the tests
listed below were performed blindly.
2.1. Sleep Test. The in-laboratory polygraph examination
was performed using a six-channel computerized polygraph
with leads for a pulse oximeter, thoracoabdominal strain
gauge, ECG, position transducer, nasal cannula pressure
transducer, and leg EMG. A static charge mattress was also
used for additional information. The home recordings were
made using a Somnologica (Flagahf, Reykjavik, Iceland) 8-
channel polygraph, which also included a nasal cannula
pressure transducer. The methods used at hospital an at
home were equally accurate. Apnoea was defined as the
absence of breathing for more than 10 sec, and an obstructive
apnoeic episode was identified as a complete cessation of
oronasal airflow as detected by the nasal pressure sensor
in the presence of continuous breathing eﬀorts revealed by
the thoracoabdominal strain gauges. Hypopnoea was defined
as a reduction of at least 50% in the airflow signal. Mixed
apnoeas and hypopnoeas were combined with obstructive
ones to form an apnoea-hypopnoea index (AHI). OSA was
diagnosed here if the AHI was ≥5/h (17).
2.2. Detection of a Patent Foramen Ovale. PFO was detected
by ear oximetry, which is a noninvasive method with high
sensitivity (85%) and specificity (100%) [9]. The oximetric
recordings were obtained by continuous measurement of
arterial oxygen saturation with a two-wavelength earpiece
oximeter connected to a computer. The signals obtained
from the optical sensors, corresponding to two photoplethys-
mograms, were digitized by an analogue-to-digital converter
inside the oximeter and then transferred to the computer.
The signals were further processed and the relative oxygen
saturation value was continuously displayed as a curve on
the screen. The signals were stored on the hard disc for
later processing and oﬀ-line analysis. Special software was
used for data processing and for the elimination of artefacts
caused by the large, rapid changes in the blood content of
the ear. To optimize the circulation of blood in the ear,
an arterializing warm-up period of 10 minutes was allowed
before the measurements were performed.
The subjects were first trained to perform both Val-
salva (VM) and Mu¨ller’s manoeuvre (MM). Then three
measurements were performed with a VM and three with
a combined VM and MM. VM consisted of blowing
into a mouthpiece attached to a standard blood-pressure
apparatus. The subjects were able to read the pressure scale
of the apparatus during their test blowing, and they were
asked to generate and hold a pressure of 40mmHg for 15
seconds. The combination of VM andMMwas accomplished
by asking the subject to inspire rapidly through the closed
mouthpiece immediately after VM. The subjects were always
in a supine position with a pillow under their head during
the recordings. PFO was considered to be present when a
transient drop in the oxygen saturation curve after release of
the provocation was seen in at least two recordings. The SaO2
drop in the oxygen saturation curve was evaluated visually
using oﬀ-line computer analysis. A typical drop lasts two to
three seconds.
2.3. Shear-Induced Platelet Aggregation. SIPA was measured
at 4-hour intervals between 6 p.m. and 6 a.m. Blood was
collected without stasis via a plastic cannula into tubes
containing 1/10 volume of 3.8% trisodium citrate. To obtain
platelet-rich (PRP) and platelet-poor plasma (PPP), parts of
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the blood samples were centrifuged at 330 g for 10 minutes
and at 1500 g for 5 minutes. Aggregation was induced by
applying a high shear force, 108 dynes/cm2, for 5 minutes
by a turbidometric technique that uses a thermostatic cone-
plate streaming chamber. The method is described in detail
elsewhere [17, 18]. SIPA was expressed as the maximum
percentage change in light transmittance during the 5-
minute period.
2.4. Determination of Prostanoids. Urine was collected after
voiding the bladder from 10 a.m. till 6 p.m. (evening sample)
and from 10 p.m. till 6 a.m. (morning sample). Samples for
the determination of 2,3-dinor-6-ketoprostaglandinF1α (2,3-
dinor-PGF1α), 11-dehydro-thromboxane B2 (11-dehydro-
TXB2), and 2,3-dinor-thromboxane B2 (2,3-dinor-TXB2)
were frozen immediately after collection and stored at
−70◦C until extraction. The prostanoids were determined by
radioimmunoassay as previously described [19].
2.5. Determination of Fibrinolytic Factors. Blood samples
were drawn into Biopool Stabilyte tubes and the plasma sep-
arated out within an hour by centrifugation at +4◦C (1 800 g
for 30min). The samples were then immediately stored at
−70◦C and thawed once at +37◦C for 30 minutes before
use. PAI-1 : Ag and PAI-1 activity were determined according
to the manufacturer’s instructions using a TintElize PAI-
1 kit and a Chromolize PAI-1 kit (Biopool International,
CA, USA), respectively. The TintElize PAI-1 assay measures
active, latent and tPA or uPA-complexed forms of PAI-1.
2.6. Statistics. Fisher’s exact two-tailed test, Pearson’s χ2
test, Student’s t-test, an analysis of variance (ANOVA), and
Spearman’s rank correlation coeﬃcients (rs) were used as
appropriate. Multiple linear regression analyses were per-
formed to establish independent associations between risk
factors and levels of fibrinolytic and haemostatic factors and
their nocturnal increments. Logarithmic transformation was
used for variables which were not normally distributed (AHI,
prostanoid metabolites). The variables taken into account in
these analyses were age, sex, history of hypertension (ormean
BP), diabetes, current smoking, use of anti-inflammatory
drugs, and AHI (or body mass index, BMI). A P value <
0.05 was considered significant. All the statistical calculations
were performed with SPSS 14.0 forWindows software (SPSS,
Inc., Chicago, IL).
3. Results
The subjects’ baseline characteristics are shown in Table 1.
Twenty-nine subjects (controls) did not have OSA (AHI <
5/h), whereas 24 did. The subjects with OSA had a higher
BMI (P = 0.012) and more frequently had hypertension
(P = 0.030) and diabetes (P = 0.036) than those without
OSA. PFO was detected in 3 subjects with OSA, who also
had a significantly higher mean blood pressure than the OSA
subjects without PFO (P = 0.041) or the control subjects
with (P = 0.018) or without PFO (P = 0.006). BMI was


























Blood samples were drawn at 6 p.m. (evening), 10 p.m. (late evening), 
2 a.m. (night) and 6 a.m. (morning).
Figure 1: PAI-1 activity (95% CI) in subjects with OSA and
controls.
whereas AHI was correlated with a history of hypertension
(rs = 0.324, P = 0.018) and with age (rs = 0.304, P = 0.027).
Two of the OSA patients had a severe condition (AHI >
40), whereas the rest (including the 3 with PFO) had mild-
to-moderate OSA (AHI 5–40). One subject had a history
of paroxysmal atrial fibrillation, but he had neither OSA
nor PFO. None of the subjects had venous thrombosis or
embolism in their history.
Changes in fibrinolytic activity and platelet function
from evening to morning are shown in Table 2. All the
subjects showed higher levels of PAI-1 : Ag and PAI-1 activity
in the morning than in the evening (circadian variation).
Figure 1 demonstrates that PAI-1 activity in the morning
was significantly higher in the subjects with OSA than in
the controls. Findings were similar if the subjects with PFO
were excluded (data not shown). The subjects with PFO also
showed high PAI-1 activities in the morning. We observed
an increment in PAI-1 : Ag from evening to morning that
correlated significantly with the presence of PFO (rs =
0.563,P = 0.002).
SIPA tended to increase from evening to morning, but
the increments did not reach statistical significance in any
of the groups. SIPA in the subjects with OSA was higher
than that in the controls at all time points, but the diﬀerence
reached statistical significance only at 10 p.m. (P = 0.049).
SIPA was significantly lower in the subjects with PFO (none
of them had used NSAIDs) than in those without PFO, but
the diﬀerence attenuated during the night (Figure 2). The
morning ratio of 2,3-dinor-TXB2 to 2,3-dinor-PGF1α was
significantly higher in the subjects with OSA than in the
controls (P = 0.006). The ratio was on the same level in the
subjects with PFO as in the controls.
To see whether OSA influences the urinary excretion
of the thromboxane and prostacyclin metabolites diﬀerently
we excluded the subjects with PFO and looked at the
metabolite levels separately during day and night (Table 3).
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Table 1: Baseline characteristics of 53 subjects investigated for OSA and PFO.










Sex (female/male) 0/3 1/20 1/5 3/20 5/48
Mean (SD) age, years 51 (3) 46 (8) 51 (15) 42 (7) 45 (9)
Mean (SD) BP, mmHg 121 (2) 115 (11) 106 (11) 112 (12) 113 (12)
Mean (SD) BMI kg/m2 31 (6) 32 (6) 27 (4) 28 (5) 30 (6)
Median (25 and 75%) AHI 19 (5, 30) 11 (8, 16) 1 (0, 2) 1 (0, 3) 4 (1, 11)
Previous history
Ischaemic vascular disease 1∗ 1† 0 1‡ 3
Atrial fibrillation 0 0 0 1 1
Diabetes mellitus 1 3 0 0 4
Hypertension 1 9 1 3 14
Current smoking 0 5 0 3 8
BP: blood pressure, BMI: body mass index (normal weight 18.5–24.9; overweight 25–29.9; obesity > 30), RDI: respiratory disturbance index.
∗Myocardial infarction.
†Myocardial infarction and ischaemic brain infarction.
‡Ischaemic brain infarction.
Table 2: Changes in fibrinolytic and platelet parameters from evening to morning.
Variable
Control∗ OSA∗ PFO†
Evening Morning Evening Morning Evening Morning
PAI-1: Ag, ng/mL 8 (6–10) 18 (12–24) 15 (10–20) 26 (17–35) 8 (4–13) 27 (9–45)
PAI-1 activity, U/mL 13 (9–16) 16 (12–20) 14 (9–18) 23 (17–29) 21 (17–25) 27 (10–43)
SIPA, % 47 (41–52) 50 (46–53) 52 (47–58) 54 (48–59) 36 (28–43) 44 (33–55)
2,3-dinor-TXB2/2,3-dinor-PGF1α 1.2 (0.9–1.4) 1.2 (1.0–1.4) 1.6 (1.0–2.2) 1.7 (1.4–2.1) 0.9 (0.5–1.3) 1.1 (0.8–1.5)
Values are means (95% CI).
Blood samples were taken at 6 p.m. (evening) and at 6 a.m. (morning).
∗Subjects with PFO are included.
†Subjects with OSA are included.
It appeared that the urinary excretion of 2,3-dinor-TXB2 did
not significantly diﬀer between the subjects with OSA and
the controls, whereas the excretion of 2,3-dinor-PGF1α was
significantly lower during night in the subjects with OSA.
Thromboxane metabolite levels in urine were found to be
influenced by the use of NSAIDs, as shown by a negative
association between use of these drugs and urinary excretion
of 2,3-dinor-TXB2 (β = −0.568; P = 0.026). We did not
observe any significant eﬀects of use of NSAIDs on the other
parameters of platelet function.
Linear regression analysis showed the presence of PFO
to be associated independently with the PAI-1: Ag increment
during the night (standardized regression coeﬃcient, β =
0.611; P = 0.015), an association that was not significantly
influenced by age, sex, hypertension, diabetes, current smok-
ing, and use of anti-inflammatory drugs or AHI. Replacing
AHI with BMI and/or hypertension with mean BP did not
alter the result. In a similar model, PFO (β = 0.594; P =
0.015) and AHI (β = 0.499; P = 0.032) showed significant
associations with PAI-1 activity in the morning. Linear
regression analysis also showed hypertension to be associated
significantly and independently with the increment in SIPA
during the night (β = 0.536; P = 0.020).
4. Discussion
We observed decreased fibrinolytic activity and increased
platelet activity in subjects with OSA after overnight sleep.
PFO was associated with an increment in PAI-1: Ag during
the night, and PFO and AHI were associated independently
with PAI-1 activity in the morning. These findings indicate
a prothrombotic state in subjects with OSA and PFO. The
cooccurrence of OSA and PFO may result in a greater
decrease of fibrinolytic activity than with either one alone.
Few investigations have been made into PAI-1 activity or
PAI-1 : Ag levels in subjects with OSA [20, 21]. Ra˚ngemark
et al. 21] found PAI-1 activity levels in patients to be
more than twice those in controls, a relation that retained
its significance after correction for age, BMI, and diastolic
blood pressure. Von Ka¨nel et al. [21] found a positive
correlation between AHI and PAI-1: Ag in OSA patients and
showed a fall in PAI-1: Ag after continuous positive airway
pressure (CPAP) treatment, suggesting that this treatment
could reverse the decreased fibrinolytic activity found inOSA
patients.
PFO seems to cause decreased fibrinolytic activity during
nocturnal sleep, but it is not known whether this is due to
transient opening of a right-to-left shunt during apnoeic
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Table 3: Urinary excretion of thromboxane and prostacyclin in subjects without PFO.
Variable
Control OSA
Day Night Day Night
11 DH-TXB2, pg/μmol creatinine 24 (8–41) 18 (9–26) 23 (19–28) 24 (16–31)
2,3-dinor-TXB2, pg/μmol creatinine 18 (11–26) 15 (11–19) 16 (12–19) 15 (12–18)
2,3-dinor-PGF1α, pg/μmol creatinine 15 (10–20) 14 (9–19) 11 (8–14) 9 (6–12)∗
2,3-dinor-TXB2/2,3-dinor-PGF1α 1.2 (0.9–1.5) 1.2 (1.0–1.5) 1.7 (1.0–2.3) 1.8 (1.5–2.1)
∗


















Subjects with OSA are included
Morning†
†P
Figure 2: SIPA in subjects with and without PFO.
periods or to some other mechanism. Our finding that the
presence of PFO predicts a PAI-1: Ag increment during
sleep is a novel one and needs confirmation. Previous data
on the relationship between PFO and coagulation factors
do not include PAI-1 (activity or antigen) [10]. SIPA was
significantly lower in the subjects with PFO than in subjects
without PFO, but it tended to increase during the night. The
reason for this remained unclear.
Low fibrinolytic activity promotes thrombogenesis dur-
ing night and may predispose the subject to brain and
myocardial infarction. PAI-1 is implicated in both thrombus
stabilization [21] and atherosclerotic disease [22], and hence
it could be a link between OSA and these diseases. Elevated
PAI-1 [23] and fibrinogen levels [24] have been observed
during the acute phase of ischaemic stroke, but it is not
clear whether they precede the stroke or are caused by it.
One study has nevertheless indicated that high levels of PAI-
1 preceded the onset of a first myocardial infarction [25].
It has been demonstrated that OSA entails an excess risk
of stroke and death from any cause after adjustment for all
major confounders, including hypertension [3].
Prostacyclin and thromboxane play a fundamental
role in the processes of platelet aggregation, vasocon-
striction/relaxation, and inflammation. We determined the
urinary excretion of their metabolites 2,3-dinor-PGF1α, 2,3-
dinor-TXB2 and 11-dehydro-TXB2 and found the ratio
between 2,3-dinor-TXB2 and 2,3-dinor-PGF1α to be higher
in subjects with OSA than in controls. This eﬀect seemed to
be due to the lower urinary excretion of 2,3-dinor-PGF1α in
subjects with OSA. Similar findings have been reported in
drug-free OSA patients [20, 26] of the same age, whereas the
opposite eﬀect has been reported in younger subjects with
OSA [27].
Platelet aggregation measured by SIPA tended to be
higher in subjects with OSA than in controls, but the
diﬀerence was not significant. Several studies using diﬀerent
methodologies have indicated increased platelet activation
and aggregation in OSA [28–31], whereas others have
found only a slight eﬀect [32] or none at all [20, 27, 33].
Some studies have also demonstrated that the increased
platelet activity seen in OSA patients can be normalized
by continuous positive airway pressure (CPAP) treatment
[28, 31, 32]. There may be a relationship between platelet
activity and OSA severity [29, 31]. Perhaps we were unable
to demonstrate a significant diﬀerence in platelet aggregation
because we had very few severe OSA cases in our material.
Platelets contain a large amount of PAI-1 and translational
active mRNA for PAI-1, and synthesize active PAI-1 after
thrombin stimulation [12]. Could the higher levels of PAI-1:
Ag and activity that we found be indirect markers of higher
platelet activation?
The untoward eﬀects of PFO and OSA on haemocoagu-
lation may act in concert to promote thrombus formation,
particularly if atrial fibrillation is present. PFO has been
thought to be a risk factor for ischaemic stroke via para-
doxical embolism, even though venous thrombosis is seldom
detected as preceding acute brain infarction in subjects
with cryptogenic stroke and PFO. Indeed, a population-
based study has suggested that PFO itself is not a risk
factor for cryptogenic ischaemic stroke [8]. The real reason
for the high prevalence of PFO in young subjects with
cryptogenic ischaemic stroke is still unclear. If such strokes
are not mediated by paradoxical embolism, could some other
mechanism be responsible, for example, in situ formation
of a thrombus in the left atrium? As right-to-left shunt
occurs during apnoeas in subjects with PFO [34], OSA
in such subjects could result in more severe hypoxia and
sympathetic activation during nocturnal sleep [35]. Hypoxia
has been postulated as inducing increased production of
reactive oxygen species and adhesion molecules in leukocytes
and the endothelium and decreased NO availability, leading
to endothelial dysfunction [36]. The consequence could be
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promotion of thrombus formation in the left atrium in the
presence of atrial fibrillation. Associations between atrial
fibrillation and OSA [6] and PFO [11] have been observed,
and both OSA and PFO may provoke atrial fibrillation, so
that they could both promote nocturnal thrombus formation
in the left atrial appendage. This could explain why OSA is
an independent risk factor for stroke and why the risk is not
mediated by hypertension [3]. The prevalence of PFO among
subjects with OSA is high [37].
The major limitation of this study is the small number
of subjects. The findings may be spurious and need confir-
mation in a larger body of material. The most important
findings were nevertheless consistent and allowed us to put
forward new hypotheses for further study. A significant acti-
vation of coagulation markers in subjects with PFO and OSA
does not necessarily imply that this is indeed the mechanism
that leads to stroke in such subjects. The observed elevated
markers of coagulation activation could also result from
confounding factors. Cardiac function was not monitored
in all the subjects. Therefore, we cannot exclude an eﬀect
of undetected atrial fibrillation on coagulation activation.
Another limitation is the fact that some subjects had been
taking nonsteroidal anti-inflammatory drugs. We did not
observe any eﬀects of these drugs on any parameter other
than the urinary excretion of thromboxane, however. It is
diﬃcult to collect a suﬃcient number of subjects with OSA
who have been free of any drug treatment. Finally, obesity
may also influence blood coagulation without OSA. Thus,
lack of a control group consisting of obese subjects without
OSA is also a weakness in our study.
The strengths of the study include the fact that we were
able to take several confounding factors, such as hyper-
tension, diabetes, smoking, and previous cardiovascular
diseases, into account when interpreting the results and that
all the measurements were performed blindly.
In conclusion, we were able to demonstrate higher levels
of PAI-1 activity and a higher ratio of 2,3-dinor-TXB2 to
2,3-dinor-PGF1α in subjects with OSA early in the morning
after overnight sleep than in controls. These observations
suggest a prothrombotic state. We also demonstrated for
the first time an increment in PAI-1 : Ag from evening to
morning that correlated significantly with the presence of
PFO. These observations suggest that subjects with both OSA
and PFO may develop a more severe prothrombotic state
during sleep than subjects having either OSA or PFO alone. A
prospective study is urgently needed to demonstrate whether
subjects having both OSA and PFO will run a greater risk
for ischaemic strokes than those without this combination.
If so, treatment of OSA may be an important option for
prevention of ischeamic strokes among such subjects.
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